Blood-generating preparation for treating male hormone alopecia as well as preparation method and application of blood-generating preparation

Abstract

The invention discloses a hematopoietic preparation for treating androgenetic alopecia and a preparation method of the hematopoietic preparation. The hematopoietic preparation is prepared from 5-30 parts of radix polygoni multiflori preparata, 5-30 parts of wine ligustrum lucidum ait, 5-30 parts of mulberry, 5-30 parts of eclipta, 5-30 parts of radix paeoniae alba, 5-30 parts of astragalus membranaceus and 5-30 parts of rhizoma cibotii. The medicine composition and the specific dosage are obtained through a large number of experimental screening and clinical medication experience screening. The whole formula takes tonifying liver and kidney and benefiting essence and blood as the monarch, and takes tonifying spleen and qi and removing heat to cool blood as the minister and assistant, based on the traditional Chinese medicine theory that essence is stored in kidney and is warmed on hair, by inhibiting DHT generation, resisting hair follicle apoptosis and improving scalp microcirculation, the traditional Chinese medicine composition has the remarkable effect of treating androgenetic alopecia, is weak in toxic and side effects, and can be prepared into various clinical dosage forms.

Description

Technical Field

[0001] This invention belongs to the field of traditional Chinese medicine technology, specifically relating to a blood-nourishing preparation for treating androgenetic alopecia, its preparation method, and its application. Background Technology

[0002] Androgenetic alopecia (AGA), also known as seborrheic alopecia, is the most common type of hair loss. It is a progressive disease caused by the miniaturization of hair follicles due to the action of androgens (mainly dihydrotestosterone, DHT) in a genetic context. Simply put, the hair follicles on the crown and forehead are particularly sensitive to androgens. Under the long-term influence of DHT, the hair follicles gradually shrink, the hair becomes thinner, shorter, and lighter in color, and eventually falls out until the hair follicles die and disappear.

[0003] The main causes and mechanisms currently believed to be... 1. Genetic factors: There is a strong familial tendency. If there is a family history of androgenetic alopecia, the individual's risk of developing the condition is significantly increased.

[0004] 2. Androgen effects: Testosterone in the body is converted into more potent dihydrotestosterone (DHT) by 5α-reductase.

[0005] Hair follicles carrying genetic susceptibility genes (usually located on the forehead and crown) are highly sensitive to DHT.

[0006] DHT attacks these hair follicles, causing their growth cycle to shorten (the anagen phase becomes shorter and the telogen phase becomes longer), the hair shaft gradually becomes thinner and softer, and eventually transforms from terminal hair (coarse and stiff hair) into vellus hair (soft body hair) until it falls out.

[0007] Clinical manifestations and classification 1. Male pattern baldness (androgenetic alopecia) Common patterns: Hair density typically begins to decrease from the sides of the forehead, with the hairline gradually receding, forming an "M-shaped" hair loss pattern; or hair loss begins from the top of the head, forming an "O-shaped" hair loss pattern. In severe cases, the two patterns can merge, leaving only hair on the back of the head and temples, forming a "C-shaped" or "U-shaped" hairline.

[0008] Classification: The Hamilton-Norwood classification system is commonly used, which divides the system into 7 levels and 12 types.

[0009] Female androgenetic alopecia Common pattern: Typically presents as diffuse thinning of hair on the top of the head, with a noticeably wider parting, but the hairline at the forehead generally remains intact. The degree of hair loss is generally less than in men.

[0010] Classification: The commonly used Ludwig classification system is divided into 3 levels.

[0011] Currently, topical milodil, oral finasteride (limited to men), and spironolactone / cyproterone acetate (mainly for women) are effective treatments for seborrheic alopecia, but long-term use has many adverse reactions.

[0012] Traditional Chinese medicine (TCM) has unique efficacy and high safety in treating hair loss. Therefore, this invention, through extensive experimental screening and optimization of formulations, develops and expands the clinical efficacy of existing TCM preparations. Providing new clinical medications for the treatment of hair loss is of great significance. Summary of the Invention

[0013] Objective of this invention: This invention, through extensive experimental screening and combined with clinical experience, identifies the composition and dosage of traditional Chinese medicine (TCM) for treating androgenetic alopecia. Another objective of this invention is to provide a method for preparing this TCM composition.

[0014] Technical solution: To achieve the above objectives, the technical solution adopted by this invention is as follows: A blood-nourishing preparation for treating androgenetic alopecia, made from the following traditional Chinese medicine ingredients: Prepared Polygonum multiflorum 5-30 parts, wine-processed Ligustrum lucidum 5-30 parts, mulberry 5-30 parts, Eclipta prostrata 5-30 parts, white peony root 5-30 parts, Astragalus membranaceus 5-30 parts, Cibotium barometz 5-30 parts.

[0015] As a preferred embodiment, the above-mentioned Shengxuebao preparation for treating androgenetic alopecia is made from the following parts by weight of traditional Chinese medicine raw materials: 5-20 parts of Ligustrum lucidum (processed), 5-20 parts of Polygonum multiflorum (processed), 5-20 parts of Morus alba, 5-20 parts of Eclipta prostrata, 5-20 parts of Paeonia lactiflora, 5-20 parts of Astragalus membranaceus, and 5-20 parts of Cibotium barometz.

[0016] As a preferred embodiment, the above-mentioned Shengxuebao preparation for treating androgenetic alopecia is made from the following parts by weight of traditional Chinese medicine raw materials: 6.45 parts of Ligustrum lucidum (processed), 6.45 parts of Polygonum multiflorum (processed), 6.45 parts of Morus alba, 6.45 parts of Eclipta prostrata, 6.45 parts of Paeonia lactiflora, 6.45 parts of Astragalus membranaceus, and 6.45 parts of Cibotium barometz.

[0017] As a preferred embodiment, the preparation method of the above-described blood-nourishing preparation for treating androgenetic alopecia includes the following steps: Weigh each Chinese herbal raw material according to the specified weight proportions, add water, soak first, then reflux to extract, filter, combine the filtrates, concentrate, add ethanol, let stand to precipitate, centrifuge, take the supernatant, concentrate, and dry to obtain the final product.

[0018] As a preferred embodiment, the preparation method of the above-described blood-nourishing preparation for treating androgenetic alopecia includes the following steps: Weigh each Chinese herbal raw material according to the specified weight proportions, add water at a weight-to-volume ratio of 1:5~20, soak for 0.5~1 hour, then extract 1~3 times, each time for 0.5~3 hours, filter, combine the filtrates, concentrate, add ethanol to make the ethanol volume concentration 60~80%, centrifuge, take the supernatant, concentrate, and dry to obtain the final product.

[0019] As a preferred embodiment, the preparation method of the above-described blood-nourishing preparation for treating androgenetic alopecia includes the following steps: Weigh each Chinese herbal raw material according to the specified weight proportions, add distilled water at a weight-to-volume ratio of 1:6~15, soak for 0.5 hours, then decoct and extract 2~3 times, each time for 0.5~2 hours, filter, combine the filtrates, concentrate, add ethanol to make the ethanol volume concentration 60~80%, centrifuge, take the supernatant, concentrate, and dry to obtain the final product.

[0020] A traditional Chinese medicine preparation for treating androgenetic alopecia, comprising extracts of the traditional Chinese medicine raw materials described in this invention.

[0021] The aforementioned traditional Chinese medicine preparations can be prepared into compound preparations, tablets, pills, granules, capsules, oral liquids, extracts, or powders by combining extracts of the traditional Chinese medicine composition with pharmaceutically acceptable carriers, according to the convenience of clinical use.

[0022] Beneficial effects: The present invention has the following technical advantages: This invention utilizes extensive experimental screening combined with clinical experience to determine the medicinal composition and specific dosage. The formula is based on the principle of "tonifying the liver and kidneys, and nourishing essence and blood," supplemented by herbs that "strengthen the spleen and replenish qi, clear heat and cool the blood." Based on the traditional Chinese medicine theory that "the kidneys store essence, which manifests in the hair," it significantly treats androgenetic alopecia by inhibiting DHT production, preventing hair follicle apoptosis, and improving scalp microcirculation.

[0023] This invention uses ELISA to detect the content in mouse serum. Results showed that the herbal composition of this invention could increase the area and length of new hair growth in the bald areas on the back of mice to varying degrees, and shorten the time for hair to darken. Scanning electron microscopy results showed that it could improve hair morphology, promote thicker and smoother hair, and denser cuticle arrangement. HE staining results of transverse and longitudinal sections of mouse back skin showed that it could increase the number of hair follicles, improve hair follicle miniaturization, and promote hair growth. Serum biochemical index detection showed that it could reduce the levels of androgens such as testosterone (T), estradiol (E2), and dihydrotestosterone (DHT) in mouse skin. It has a significant therapeutic effect on AGA (acute alopecia areata). Furthermore, it has low toxicity and can be prepared into various clinical dosage forms. Attached Figure Description

[0024] Figure 1 The effect of SXB on mouse body weight ( (n=10).

[0025] Figure 2 shows the hair growth in the bald area of ​​the mouse.

[0026] Figure 3 For mouse color scoring indicators and color score quantification charts (n=3, compared with the normal group), ### p <0.001; compared with the model group, * p <0.05,** p <0.01, *** p <0.001. Figure 4 The hair coverage of mice (n=3, compared with the normal group) was used to measure the hair coverage of mice. ### p <0.001; compared with the model group, * p <0.05,** p <0.01, *** p <0.001. Figure 5 This is a SEM image of mouse hair.

[0027] Figure 6 Images of HE staining of the dorsal skin of mice in each group (×200).

[0028] Figure 7 The number and length of hair follicles in each group of mice (n=3, compared with the normal group) were measured. ### p <0.001; compared with the model group, * p <0.05,** p <0.01, *** p <0.001. Figure 8 The levels of DHT, T, and E2 in mouse serum (n=6, compared with the normal group) ### p <0.001; compared with the model group, * p <0.05,** p <0.01, *** p <0.001. Detailed Implementation

[0029] The present invention will be further illustrated below with reference to specific embodiments. It should be understood that these embodiments are for illustrative purposes only and are not intended to limit the scope of the invention. After reading the present invention, any modifications of the present invention in various equivalent forms by those skilled in the art will fall within the scope defined by the appended claims.

[0030] Example 1 1. A blood-nourishing preparation for treating androgenetic alopecia, made from the following traditional Chinese medicine raw materials in parts by weight: 645g of Ligustrum lucidum (processed), 645g of Polygonum multiflorum (processed), 645g of Morus alba, 645g of Eclipta prostrata, 645g of Paeonia lactiflora, 645g of Astragalus membranaceus, and 645g of Cibotium barometz.

[0031] 2. A method for preparing a blood-nourishing preparation for treating androgenetic alopecia, comprising the following steps: Weigh the above-mentioned Chinese herbal raw materials according to the specified weight proportions, add distilled water at a weight-to-volume ratio of 1:12, soak for 0.5 hours, decoct and extract for 2 hours, filter to obtain filtrate; add distilled water to the residue at a weight-to-volume ratio of 1:10, decoct and extract for 1 hour, filter to obtain filtrate; add distilled water to the residue at a weight-to-volume ratio of 1:8, decoct and extract for 1 hour, filter to obtain filtrate; combine the filtrates from the three decoctions, concentrate, add ethanol to the concentrate to make the ethanol volume concentration 70-80%, centrifuge, take the supernatant, concentrate, add sucrose as an excipient, sterilize, and fill to prepare 1000mL of the mixture.

[0032] Example 2 1. A blood-nourishing preparation for treating androgenetic alopecia, made from the following traditional Chinese medicine raw materials in parts by weight: Prepared Polygonum multiflorum 300g, wine-processed Ligustrum lucidum 300g, mulberry 300g, Eclipta prostrata 300g, white peony root 300g, Astragalus membranaceus 300g, Cibotium barometz 300g.

[0033] 2. A method for preparing a blood-nourishing preparation for treating androgenetic alopecia, comprising the following steps: Weigh the above-mentioned Chinese herbal raw materials according to the specified weight proportions, add distilled water at a weight-to-volume ratio of 1:10, soak for 0.5 hours, decoct and extract for 2 hours, filter to obtain filtrate; add distilled water to the residue at a weight-to-volume ratio of 1:8, decoct and extract for 1.5 hours, filter to obtain filtrate; add distilled water to the residue at a weight-to-volume ratio of 1:6, decoct and extract for 1 hour, filter to obtain filtrate; combine the filtrates from the three decoctions, concentrate, add ethanol to the concentrate to make the ethanol volume concentration 70-80%, centrifuge, take the supernatant, concentrate, add starch and cyclodextrin to prepare tablets.

[0034] Example 3 1. A blood-nourishing preparation for treating androgenetic alopecia, made from the following traditional Chinese medicine raw materials in parts by weight: Prepared Polygonum multiflorum 50g, wine-processed Ligustrum lucidum 50g, mulberry 50g, Eclipta prostrata 50g, white peony root 50g, Astragalus membranaceus 50g, Cibotium barometz 50g.

[0035] 2. A method for preparing a blood-nourishing preparation for treating androgenetic alopecia, comprising the following steps: Weigh each of the above traditional Chinese medicine raw materials according to the number of parts by weight, add distilled water at a weight-to-volume ratio of 1:10, soak for 1 hour first, decoct and extract for 1 hour, filter to obtain a filtrate; add distilled water to the medicinal residues at a weight-to-volume ratio of 1:8, decoct and extract for 1 hour, filter to obtain a filtrate; add distilled water to the medicinal residues at a weight-to-volume ratio of 1:6, decoct and extract for 1 hour, filter to obtain a filtrate; combine the filtrates obtained from the three decoction extractions, concentrate, add ethanol to the concentrated solution to make the volume concentration of ethanol 70 - 80%, centrifuge, take the supernatant, concentrate, add starch and cyclodextrin to granulate, and encapsulate to prepare capsules.

[0036] Example 4 1 Experimental materials 1.1 Experimental animals Male C57BL / 6 mice, 6 weeks old, weighing 19 - 21 g, provided by Sichuan Dashuo Experimental Animal Co., Ltd. (Experimental Animal Production License Number: SCXK (Sichuan) 2025 - 0030), housed in a fully enclosed SPF-level environment in the Experimental Animal Center of Shaanxi University of Chinese Medicine, at a room temperature of 20 ± 2°C, relative humidity of 40% - 70%, with 12 h of alternating light and darkness every day, and free access to food and water.

[0037] Minoxidil (Batch number: 20241116A); Finasteride (Hangzhou Merck Sharp & Dohme Pharmaceutical Co., Ltd.); DHT (Shanghai Yika Biotechnology Co., Ltd., Batch number: EK250312); Corn oil (Shanghai Yuanye Biotechnology Co., Ltd., Batch number: J06IS219249); Mouse testosterone (T) ELISA kit (Jiangsu Enzyme Immunoassay Industry Co., Ltd., Batch number: 202507); Mouse estradiol (E2) ELISA kit (Jiangsu Enzyme Immunoassay Industry Co., Ltd., Batch number: 202507); Mouse dihydrotestosterone (DHT) ELISA kit (Jiangsu Enzyme Immunoassay Industry Co., Ltd., Batch number: 202507).

[0038] 1.4 Main instruments Milli-Q ultrapure water system (Millipore Corporation, USA); MS-105DU electronic analytical balance (Mettler Toledo Instruments (Shanghai) Co., Ltd.); Optical microscope (Nikon, Japan); Multifunctional microplate reader (BioTek Instruments, Inc., USA); Thermostatic plate mixer (Eppendorf AG, Germany).

[0039] 2 Methods 2.1 Modeling method and drug administration Six-week-old male C57BL / 6 mice were randomly divided into four groups (n=10 per group) after a one-week acclimatization period, including a control group, a model group, a low-dose group (SXB-L), a medium-dose group (SXB-M), a high-dose group (SXB-H), a milodil group (Min), and a finasteride group (Fin). Mice were anesthetized with isoflurane, and the hair on their backs (3×2 cm) was shaved, with residual hair removed using depilatory cream. From the start to the end of the experiment, except for the control group, all other groups received a daily subcutaneous injection of 0.5 mg DHT in the neck and back to induce an AGA model. After 7 days of treatment, starting on day 7, 4 hours after the subcutaneous injection of DHT, the treatment groups and the positive control group began gavage therapy. The control group and the model group received an equal dose of physiological saline via gavage. The treatment lasted for 21 days, with a total experimental period of 35 days. In addition to normal feeding, mice in each group were treated daily by gavage with the following medications: the control group and the model group were administered 0.4 mL of double-distilled water by gavage. Based on literature, the drug dosage for mice should be 5–10 times the human dose. The SXB-L, SXB-M, and SXB-H groups were administered 0.4 mL of Shengxuebao compound by gavage at doses of 7.81, 15.62, and 31.24 g / kg, respectively; the Min group was treated with 0.1 mL / day applied topically; and the Fin group was administered 0.4 mL of finasteride by gavage at a dose of 10 mg / kg. 2.2 Detection of hair regrowth rate in mice. The skin color changes and hair growth of mice were observed. Photographs were taken on days 0, 8, 12, 16, 20, 24, and 28 after anesthesia. Referring to the scoring criteria in the literature and considering the actual situation, the hair regrowth of each mouse was scored. The scoring criteria were as follows: 1 point indicates pink skin, the state immediately after hair loss, with a relatively obvious red color, at which point the hair follicles are in the resting phase; 2 points indicates pinkish-white skin, with less obvious red color but no gray color yet, at which point the hair follicles are entering the early growth phase; 3 points indicates white skin with obvious gray color but no black color yet, at which point the hair follicles are in the early growth phase; 4 points indicates gray skin with localized blackening and occasional short hairs, at which point the hair follicles are in the middle growth phase; 5 points indicates dark gray skin covered with short hairs, at which point the hair follicles are in the middle to late growth phase; 6 points indicates skin covered with long black hairs, at which point the hair follicles are in the late growth phase. According to the above scoring criteria, three people scored the hair growth of the mice, and the average score was taken as the final score. On day 28, the hair coverage area and the area of ​​the hair loss area were measured using ImageJ and calculated according to Formula 1.

[0040] 2.3 Newborn hair quality testing New hair regrowth was randomly selected from the bald areas and photographed using a scanning electron microscope (SEM). The thickness of the hair and the length of the hair cuticles at the mid-section were observed to evaluate the size of the hair cuticles and to comprehensively assess the quality of the new hair regrowth in mice.

[0041] 2.4 Observation of skin tissue pathological changes by hematoxylin-eosin (HE) staining Fixed skin tissue was dehydrated and cleared using gradient concentrations of ethanol and xylene. The tissue was then immersed in molten paraffin and embedded in an embedding cassette. The paraffin block was removed from the cassette, trimmed, and cut into 5 μm thick sections using a paraffin microtome. These sections were placed in hot water until fully expanded, then mounted on adhesive-coated slides and dried in an oven to obtain paraffin sections of skin tissue. Further dewaxing and rehydration of the paraffin sections were performed using xylene and gradient concentrations of ethanol. Nuclear staining was then performed using hematoxylin. Differentiation and blueing were further induced using 1% hydrochloric acid ethanol and 1% dilute ammonia. Cytoplasmic staining was then performed using eosin. Finally, dehydration and clearing were performed using gradient concentrations of ethanol and xylene, and a small amount of neutral resin was added to secure the coverslip, resulting in HE-stained sections of skin tissue. The panoramic scanner of the digital slicing system was used for observation, and the counting function of ImageJ was used to count the number and length of melanin-containing hair follicles in each slice.

[0042] 2.5 ELISA detection of T, DHT and E2 levels in skin tissue Following the kit instructions, the standards were diluted to specific concentrations. Blank wells, standard wells, and sample wells were prepared on an ELISA plate. 10 μL of serum sample was mixed with 40 μL of sample diluent. The sample and standards were then added sequentially to the 96-well plate. After mixing with 100 μL of horseradish peroxidase (HRP)-labeled detection antibody, the plate was sealed and incubated at 37°C for 60 min. The plate was then washed, and 50 μL each of solutions A and B from the kit were added. The plate was incubated at 37°C in the dark for 15 min. 50 μL of stop solution was added to each well. The absorbance at 450 nm was measured within 15 min, and the absorbance (A) of each well was read using an ELISA reader. Finally, the contents of T, DHT, and E2 in each sample were calculated.

[0043] 2.6 Statistical Methods Statistical analysis was performed using Graph Pad Prism 8.3.0 software. The t-test was used for comparisons between groups, and p < 0.05 was considered statistically significant.

[0044] 3 Experimental Results 3.1 Effects of SXB on mouse body weight Throughout the experimental period, the body weight of mice in all groups increased slowly with prolonged feeding time. Figure 1 .

[0045] 3.2 Effects of SXB on hair growth in mice See the hair growth pattern in the bald areas of the mouse. Figure 2 The statistical results after scoring are shown below. Figure 3 From day 12 onwards, the hair growth rate in the model group mice was significantly slower compared to the control group. Compared to the model group, the positive control drugs minoxidil, finasteride, and low, medium, and high doses of SXB all accelerated hair growth in mice, with SXB-H, minoxidil, and finasteride showing the most significant effects. Hair coverage is commonly used in the literature to evaluate hair regrowth in mice; the results of hair coverage at different time points in this experiment are shown below. Figure 4 Starting on day 12, the mice entered the anagen phase of hair growth. Compared with the model group, the hair coverage in the treatment group and the positive drug group was significantly increased, indicating that Shengxuebao compound had a significant effect on androgenetic alopecia, and the hair growth promotion effect showed a certain dose-related correlation.

[0046] 3.3 Effects of SXB on the quality of newly grown hair in mice Using SEM to photograph mouse hair allows for direct observation of changes in hair diameter and cuticle size, evaluating the quality of newly grown hair. Coarse new hair with large cuticles indicates better hair quality. In this experiment, the normal group had coarse hair shafts covered with densely packed, layered cuticles, while the model group had thin hair shafts with sparse cuticles and wrinkled surfaces. Compared to the model group, the SXBM and positive control groups showed significantly thicker, smoother hair shafts with densely packed, layered cuticles. SXB-H, milodil, and finasteride showed the most significant effects in improving hair morphology. Figure 5 .

[0047] 3.4 Effects of SXB on the number and length of hair follicles in mouse skin Cross-sectional results showed that the normal group had a higher hair follicle density and more intact follicles; the model group had a lower hair follicle density, with hair follicle cell apoptosis and miniaturization; the minoxidil, finasteride, and medium- and high-dose SXBM groups had higher hair follicle density, more significant melanin formation in the hair shaft, and improved hair follicle miniaturization, while the low-concentration group showed poor overall improvement in hair follicles. Longitudinal results showed that the normal group had a greater number of hair follicles, which were neatly arranged and intact; the model group, due to DHT-induced hair follicle atrophy, had shorter and fewer hair follicles. Minoxidil, finasteride, and medium- and high-concentration SXBM can promote AGA hair regeneration and improve hair miniaturization. Figure 6 For quantitative calculation of hair follicle number and length using HE staining, see [link to HE staining]. Figure 7 .

[0048] 3.5 Effects of SXB on serum levels of T, DHT, and E2 in mice Compared with the control group, the serum DHT, T, and E2 levels in the model group mice were significantly increased; compared with the model group, the serum DHT and E2 levels in the drug-treated group and the positive drug group were significantly decreased, and the T level in the minoxidil, finasteride, and high-dose SXB groups was significantly decreased. Figure 8 .

[0049] In summary, this invention establishes a mouse model of androgenetic alopecia by subcutaneous injection of DHT. By comparing the area of ​​new hair growth, the quality and length of new hair growth, the ratio of melanin-containing hair follicles to the total number of hair follicles in the skin tissue, and the length of hair follicles in the mouse back hair loss area, and by detecting the levels of T, DHT, and E2 in mouse serum, the results show that SXB has a significant therapeutic effect on androgenetic alopecia.

Claims

1. A blood builder formulation for treating androgenetic alopecia, characterized in that, It is made of the following Chinese medicine raw materials: Prepared Radix Polygoni Multiflori 5 ~ 30 parts, Wine Female Ligustrum Fruit 5 ~ 30 parts, Mulberry 5 ~ 30 parts, Eclipta 5 ~ 30 parts, White Peony Root 5 ~ 30 parts, Milkvetch 5 ~ 30 parts, Dog spine 5 ~ 30 parts.

2. The Shengxuebao preparation for treating androgenetic alopecia according to claim 1, characterized in that, It is made of the following weight parts of Chinese medicine raw materials: Wine Female Ligustrum Fruit 5 ~ 20 parts, Prepared Radix Polygoni Multiflori 5 ~ 20 parts, Mulberry 5 ~ 20 parts, Eclipta 5 ~ 20 parts, White Peony Root 5 ~ 20 parts, Milkvetch 5 ~ 20 parts, Dog spine 5 ~ 20 parts.

3. The Shengxuebao preparation for treating androgenetic alopecia according to claim 2, characterized in that, It is made of the following weight parts of Chinese medicine raw materials: Wine Female Ligustrum Fruit 6.45 parts, Prepared Radix Polygoni Multiflori 6.45 parts, Mulberry 6.45 parts, Eclipta 6.45 parts, White Peony Root 6.45 parts, Milkvetch 6.45 parts, Dog spine 6.45 parts.

4. A method of preparing a Shengxuebao preparation for treating androgenetic alopecia according to any one of claims 1 to 3, characterized in that, It includes the following steps: According to the weight parts of each Chinese medicine raw material, add water, soak first, then reflux extraction, filter, combine the filtrate, concentrate, add ethanol, stand for precipitation, centrifugal, take the supernatant, concentrate, dry, and get it.

5. A method of preparing a Shengxuebao preparation for treating androgenetic alopecia according to claim 4, characterized in that, It includes the following steps: According to the weight parts of each Chinese medicine raw material, add water according to the weight volume ratio of 1:5 ~ 20, soak for 0.5 ~ 1 hour first, then extract 1 ~ 3 times, 0.5 ~ 3 hours each time, filter, combine the filtrate, concentrate, add ethanol, make the ethanol volume concentration 60 ~ 80%, centrifugal, take the supernatant, concentrate, dry, and get it.

6. A method of preparing Shengxuebao preparation for treating androgenetic alopecia according to claim 5, characterized in that, It includes the following steps: According to the weight parts of each Chinese medicine raw material, add distilled water according to the weight volume ratio of 1:6 ~ 15, soak for 0.5 hours first, then extract by decoction 2 ~ 3 times, 0.5 ~ 2 hours each time, filter, combine the filtrate, concentrate, add ethanol, make the ethanol volume concentration 60 ~ 80%, centrifugal, take the supernatant, concentrate, dry, and get it.

7. The use of the Shengxuebao preparation of any one of claims 1 ~ 3 in the preparation of a medicament for treating androgenetic alopecia.

8. A traditional Chinese medicine preparation for treating androgenetic alopecia, characterized in that, It includes the extract of the Chinese medicine raw material of any one of claims 4 ~ 6.

9. The traditional Chinese medicine preparation according to claim 8, characterized in that, The extract of the Chinese medicine composition is prepared into a mixture, tablet, pill, granule, capsule, oral liquid, extract or powder with a pharmaceutically acceptable carrier.

Images